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According to the second deﬁnition it was respectively,
43,63% and 25,64%. Cost of the doctors’ consultations
in the perindopril group was lower by 16,52% than in
the enalapril group, which represents a saving of €19,29
per patient per year. Indirect costs reduction in the
perindopril group amounted to €131,26 per patient per
year which means -54,06%. Total cost in the perindopril
group, was lower by €55,44 per patient per year than in
the enalapril group. Calculation of the cost-effectiveness
ratios according to the ﬁrst deﬁnition (Wp = 1020; WE =
1439) and the second deﬁnition (Wp = 1226; WE = 2303)
revealed the treatment with perindopril as a more cost-
effective than enalapril. CONCLUSION: The results of
the analysis revealed signiﬁcant cost reductions and better
blood pressure control in the perindopril group as com-
pared to the enalapril group. The savings in the perindo-
pril group resulted from the reduction of the physicians’
consultation costs and from the considerable reduction of
the indirect costs.
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OBJECTIVES: Two models of ambulatory oral anticoag-
ulation management have been adopted in a teaching hos-
pital in Hong Kong, namely the anticoagulation clinic
(AC) and routine medical care (RMC). The objective of
this study was to compare the cost and outcomes of war-
farin therapy management at AC and RMC from the per-
spective of a public health organization. METHODS:
A retrospective observational study was performed by
reviewing the medical records of outpatients who were
initiated on warfarin from January 1, 1999 to June 30,
2001 in a teaching hospital. Effectiveness was assessed by
percentage of patient-time spent in target INR range and
the incidence of thromboembolic events (TE). Safety was
assessed by incidence of hemorrhage and warfarin over-
dose (INR > 5). Direct medical cost associated with the
management of warfarin therapy and anticoagulation
complications was also evaluated. The incidences were
expressed as percentage per patient-year. RESULTS:
Forty-one patients (71 patient-years) and 476 patients
(409 patient-years) were started on warfarin in AC and
RMC, respectively, during the study period. Patients
managed by AC spent signiﬁcantly more time in target
INR range than those in RMC group (58% vs. 44%; p =
0.002) and had a lower incidence of INR > 5 (1.4% vs.
7.1%; p = 0.068). The AC group patients had a lower
rate of TE (4.2% vs. 7.6%; p = 0.443) and major to fatal
bleeding (0% vs. 9.5%; p = 0.01). The total direct medical
cost of AC was lower than that of RMC by 44%
(HKD4838 vs. HKD8595 per patient year; 1USD =
7.8HKD). CONCLUSION: The establishment of the AC
improved the effectiveness, safety, and decreased the
direct medical cost of oral anticoagulation therapy.
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OBJECTIVES: Cardiovascular diseases (CVD) are one of
the leading causes of morbidity and mortality in Italy.
Atorvastatin treatment has shown to be effective in con-
trolling cholesterol levels in hyperlipidemic subjects.
Scope of this analysis is to evaluate the pharmacoeco-
nomic proﬁle of Atorvastatin compared to other statins
in subjects with a global CVD yearly risk >2%.
METHODS: Alternatives: Atorvastatin (low dose) vs
other statins (low dose) on the Italian market (weighted
with the current market shares, Atorvastatin excluded).
Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis on 2 hypothetical cohorts of
1000 subjects in primary prevention, with a global CVD
yearly risk >2%; an incremental cost per life year gained
(LYG) has been calculated. Time: 5 years. Costs: drugs
and direct medical costs quantiﬁed by using NHS tariffs
expressed in Euro 2002. Effects: the effects of different
statins in controlling cholesterol levels, as measured with
the CURVES study (Jones P et al, Am J Cardiol 1998),
have been used to model mortality and morbidity from
CVD with the Framingham Risk Equations (Anderson
KM et al, Am Heart J 1990). RESULTS: In the Atorvas-
tatin group the cost of drug therapy and events was
€2.213.415 for 58 LYG, resulting in an incremental cost
per LYG of €38.178. With other statins the cost of drug
therapy and events was €2.569.512 for 49 LYG, result-
ing in an incremental cost per LYG of €52.933. The 
differences always favoured the subjects treated with
Atorvastatin. CONCLUSIONS: This economic evalua-
tion shows that Atorvastatin is dominant over the treat-
ment with other statins as currently prescribed, as it
allows a higher number of LYG and is less costly.
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OBJECTIVE: A recent randomized clinical trial demon-
strated that improvement in moderate to severe conges-
tive heart failure (CHF) with treatment for anemia. To
estimate the health economic implications of treating
anemia with subcutaneous erythropoietin and intra-
venous iron in patients with moderate to severe CHF.
METHODS: A Markov model of CHF was developed
using New York Heart Association (NYHA) classes as the
main states and the effects of anemia treatment on these.
